



## Haemopoietic Progenitor Cell (HPC) Sector Clinical Advisory Group Governance

August 2022

### Purpose of this document

To outline the governance of the Haemopoietic Progenitor Cell (HPC) Sector Clinical Advisory Group (Advisory Group).

### Background

The National HPC Framework (the Framework) was endorsed by all Australian governments in October 2021. The Framework represents commitment from all governments to provide a policy basis for the effective, evidence-based future operations and management of the Australian HPC sector.

### Purpose and Role of the Advisory Group

The Advisory Group will support the implementation of the Framework through providing expert subject matter advice on the HPC sector to the Commonwealth-led Jurisdictional HPC Committee (JHPCC). The JHPCC facilitates policy agreement and funding of unrelated HPC donation services for patients requiring HPC transplants across Australia.

### Membership

The members will consist of HPC sector experts with a range of expertise including clinical, pathology, government/public health accreditation and regulations.

### Duration of Membership

Members will be initially appointed for up to a 24-month term.

### Declarations of Interest

The Department of Health and Aged Care's Conflict of Interest Policy (Policy) applies to all members. The Policy enables members to be aware of their obligation to disclose any relevant interests that they may have, and to ensure that they effectively and consistently manage any conflicts of interest.

### Secretariat Support

Secretariat Support for the Advisory Group will be provided by the Blood Policy and Programs Section and can be contacted via [HPCPolicyPrograms@health.gov.au](mailto:HPCPolicyPrograms@health.gov.au)